NCT03026517View on ClinicalTrials.gov

Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

January 21, 2025

Study Completion Date

January 21, 2025

Conditions

Melanoma

Interventions

DRUG

Dabrafenib

DRUG

Trametinib

DRUG

Phenformin

Trial Locations (3)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

02114

Massachusetts General Hospital, Boston

All Listed Sponsors

collaborator

Massachusetts General Hospital

OTHER

collaborator

Weill Medical College of Cornell University

OTHER

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT03026517 - Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma | Biotech Hunter | Biotech Hunter